logo
ResearchBunny Logo
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer

Medicine and Health

Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer

K. Shitara, K. Muro, et al.

In the exciting Phase 3 PARADIGM trial involving 733 participants, researchers investigated how circulating tumor DNA (ctDNA) gene alterations impact treatment outcomes in RAS wild-type metastatic colorectal cancer. Discover whether first-line therapy using panitumumab could provide longer survival rates for patients without ctDNA alterations, as highlighted by the team of experts led by Kohei Shitara and Kei Muro.

00:00
00:00
Playback language: English
Citation Metrics
Citations
0
Influential Citations
0
Reference Count
0

Note: The citation metrics presented here have been sourced from Semantic Scholar and OpenAlex.

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny